Generic Medicine Info
Indications and Dosage
Adult: Initially, 25 mg bid-tid, gradually increased to 225 mg daily if necessary.
Elderly: Initially, 25 mg daily.
Preexisting CV insufficiency; severe liver disease; children; overactive patients.
Special Precautions
Urinary retention, prostatic hypertrophy, untreated angle-closure glaucoma, pheochromocytoma; history of epilepsy; CV disease; impaired liver function; diabetes; risk of suicide; may precipitate mania or psychotic symptoms when used for CNS disorders; withdraw gradually; may impair ability to operate machinery. Pregnancy and lactation. Elderly.
Adverse Reactions
Restlessness, insomnia, anticholinergic effects, tachycardia, orthostatic hypotension, drowsiness, GI upset, testicular enlargement, impotence. Withdrawal symptoms.
Drug Interactions
Additive toxicity with antimuscarinics, CNS depressants. Response to TCA may be accelerated with thyroid hormones; pressor effects of sympathomimetics may be enhanced; risk of serotonin syndrome when taken with other antidepressants. Antidiabetic dosage may need to be adjusted.
Description: Melitracen is a TCA with anxiolytic properties.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Melitracen from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in